Last reviewed · How we verify
Rivastigmine Patch 9.5 cm2
Rivastigmine is a cholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down.
Rivastigmine is a cholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down. Used for Mild to moderate Alzheimer's disease, Mild to moderate Parkinson's disease dementia.
At a glance
| Generic name | Rivastigmine Patch 9.5 cm2 |
|---|---|
| Sponsor | University of California, San Francisco |
| Drug class | Cholinesterase inhibitor |
| Target | Acetylcholinesterase and butyrylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase, leading to increased concentrations of acetylcholine in the central nervous system. This enhancement of cholinergic neurotransmission helps improve cognitive function and behavioral symptoms in neurodegenerative diseases characterized by cholinergic deficits. The transdermal patch formulation provides continuous drug delivery over 24 hours.
Approved indications
- Mild to moderate Alzheimer's disease
- Mild to moderate Parkinson's disease dementia
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Anorexia
- Dizziness
- Headache
- Application site erythema
Key clinical trials
- Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease (PHASE3)
- The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems (PHASE4)
- Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 (PHASE4)
- Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivastigmine Patch 9.5 cm2 CI brief — competitive landscape report
- Rivastigmine Patch 9.5 cm2 updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI